Targeting key proximal drivers of type 2 inflammation in disease
The DOI matches its Crossref record; 154 of the 156 references it cites were found in a registry or an index.
Abstract
Systemic type 2 inflammation encompassing T helper 2 (TH2)-type responses is emerging as a unifying feature of both classically defined allergic diseases, such as asthma, and a range of other inflammatory diseases. Rather than reducing inflammation with broad-acting immunosuppressants or narrowly targeting downstream products of the TH2 pathway, such as immunoglobulin E (IgE), efforts to target the key proximal type 2 cytokines - interleukin-4 (IL-4), IL-5 and IL-13 - represent a promising strategy to achieve therapeutic benefit across multiple diseases. After several initial disappointing clinical results with therapies targeting IL-4, IL-5 or IL-13 in asthma, applying a personalized approach achieved therapeutic benefit in an asthma subtype exhibiting an 'allergic' phenotype. More recently, efficacy was extended into a broad population of people with asthma. This argues that the Type 2 inflammation is broadly relevant across the severe asthma population if the key upstream drivers are properly blocked. Moreover, the simultaneous inhibition of IL-4 and IL-13 has shown significant clinical activity in diseases that are often co-morbid with asthma - atopic dermatitis and chronic sinusitis with nasal polyps - supporting the hypothesis that targeting a central 'driver pathway' could benefit multiple allergic diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lebrikizumab does not affect the binding of IL-13 to the IL-13Rα2 receptor chain, the biological role of which remains unclear81.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [81]
Citations
Cites
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Asher, M. I., Montefort, S., Björkstén, B., Lai, C. K., Strachan, D. P., Weiland, S. K., & Williams, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69283-0 · Cited by 4,223
Interleukin-13: Central Mediator of Allergic Asthma
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., & Donaldson, D. D. (1998) · Science · doi:10.1126/science.282.5397.2258 · Cited by 2,617
Development and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473
Fokkens, W. J., Lund, V. J., Mullol, J., Bachert, C., Alobid, I., Baroody, F., Cohen, N., Cervin, A., Douglas, R., Gevaert, P., et al. (2012) · Rhinology journal · doi:10.4193/rhino12.000 · Cited by 2,387
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., D'Agostino, R., Castro, M., Curran-Everett, D., Fitzpatrick, A. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0896oc · Cited by 2,129
Research works printed but not linked: 5
- Pawankar, R., Canonica, G., Holgate, S. & Lockey, R. WAO White Book on Allergy 2011–2012: Executive Summary (World Allergy Organization, 2011).
- Wenzel, S. E. et al. Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. Eur. Respir. J. 36 (Suppl. 54), 713s (2010).
- Wenzel, S. et al. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled asthmatics with baseline eosinophil levels above and below 300 cells/μl. Am. J. Respir. Crit. Care Med. 191, A3632 (2015).
- Kaiser, J. Medical Officer's Efficacy Review, Genentech, Omalizumab BLA STN 103976/0. US Food and Drug Administration [online] , (2003).
- Groves, R., Wilbrahams, D., Fuller, R. & Longphre, M. Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema. J. Invest. Dermatol. 127 (Suppl. 1s), S54 (2007).
Cited by
Items 401–500 of 800
Dermal fibroblasts respond to IL-4 and IL-13 and promote T cell recruitment in atopic dermatitis
Numata, T., Shia, M., Nakamura, Y., Li, F., Chan, H., Nakatsuji, T., Cavagnero, K. J., Simmons, J., Li, H., Joshi, A. A., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci196108 · Cited by 10
Sher, L., Passalacqua, G., Taillé, C., Cohn, L. E., Daizadeh, N. S., Pandit‐Abid, N., Soler, X., Khodzhayev, A., Jacob-Nara, J. A., Deniz, Y. M., et al. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.12.002 · Cited by 10
Wang, Y., Wu, Y., Gu, C., Wang, S., Yin, H., Zhu, R., Wang, C., Li, Z., Yao, X., & Li, W. (2023) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2023.06.002 · Cited by 9
Meldrum, K., Evans, S. J., Burgum, M. J., Doak, S. H., & Clift, M. J. D. (2024) · Particle and Fibre Toxicology · doi:10.1186/s12989-024-00584-8 · Cited by 9
Paganini, C., Spelta, S., Tofani, L., Talamonti, M., Bianchi, L., Coassin, M., Zazzo, A. D., & Galluzzo, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133818 · Cited by 9
Chen, S., Gao, J., & Zhang, T. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100942 · Cited by 11
Wang, Y., Jia, R., Hu, Q., Tao, X., He, Q., Luo, G., Xiong, Q., Zhang, Z., Xiao, Y., & Liu, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1419164 · Cited by 11
Immunological Targets of Biologic Drugs in Allergic Skin Diseases in Children
Filippo, P. D., Russo, D., Attanasi, M., Pillo, S. D., & Chiarelli, F. (2021) · Biomedicines · doi:10.3390/biomedicines9111615 · Cited by 10
Suppression of Allergic Asthma by Loss of Function of Miz1-mediated Th1 Skewing
Do-Umehara, H. C., Chen, C., Zhang, Q., Schleimer, R. P., Budinger, G. R. S., & Liu, J. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0135oc · Cited by 9
Coavoy-Sánchez, S. A., Cerqueira, A., Teixeira, S. A., Santagada, V., Andreozzi, G., Corvino, A., Scognamiglio, A., Sparaco, R., Caliendo, G., Severino, B. U., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071907 · Cited by 9
Fritzsching, B. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00031 · Cited by 9
Epithelial cells in chronic obstructive pulmonary disease exacerbations: Targets for lung repair
Ji, W., Bilgiç, H. A., van den Berge, M., Kerstjens, H. A. M., Folkerts, G., Gosens, R., & Braber, S. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100131 · Cited by 9
Targeting the JAK/STAT pathway in atopic dermatitis
Cui, L., Liu, P., Wu, K., Han, X., & Peng, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1757562 · Cited by 12
Jiang, P., Wu, Y., Liu, L., Zhang, L., & Song, Z. (2022) · BMC Immunology · doi:10.1186/s12865-022-00531-2 · Cited by 9
Jiang, L., Tang, H., Lin, T., Jiang, Y., Li, Y., Gao, W., Deng, J., Huang, Z., Chen, C., Shi, J., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.02.013 · Cited by 8
Fu, Z., Gu, Q., Wang, L., Chen, L., Zhou, L., Jin, Q., Li, T., Zhao, Y., Wu, S., Luo, X., et al. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1373419 · Cited by 8
Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
Migayron, L., Bordes, S., Closs, B., Sénéschal, J., & Boniface, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1405215 · Cited by 9
Current aspects of pathogenesis and treatment of atopic dermatitis
Потекаев, Н. Н., Николаевич, С. Д., Mikhailova, I. A., Anokhina, L. S., Fedotova, K. Y., & Georgadze, N. G. (2019) · Russian Journal of Clinical Dermatology and Venereology · doi:10.17116/klinderma201918031259 · Cited by 9
Impact of COVID-19 on patients with atopic dermatitis
Grieco, T., Chello, C., Sernicola, A., Muharremi, R., Michelini, S., Paolino, G., Carnicelli, G., & Pigatto, P. D. M. (2021) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2021.07.008 · Cited by 10
Papi, A. A., Corren, J., Castro, M., Domingo, C., Rogers, L. J., Chapman, K. R., Jackson, D. J., Daizadeh, N. S., Pandit‐Abid, N., Gall, R., et al. (2022) · Allergy · doi:10.1111/all.15456 · Cited by 9
Tohda, Y., Nakamura, Y., Fujisawa, T., Ebisawa, M., Msihid, J., Djandji, M., Ortiz, B. D., Jacob-Nara, J. A., Deniz, Y. M., Rowe, P. J., et al. (2022) · Allergology International · doi:10.1016/j.alit.2022.07.008 · Cited by 9
Brancaccio, R., Murdaca, G., Casella, R., Loverre, T., Bonzano, L., Nettis, E., & Gangemi, S. (2023) · Biomedicines · doi:10.3390/biomedicines11051266 · Cited by 9
Kang, H., Hernandez‐Con, P., Heo, J. H., Wilson, D. L., Blake, K., Lang, J. E., & Park, H. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.7.721 · Cited by 8
A pediatric case of dupilumab-induced pustular psoriasis
Dang, N., Zheng, H., & Ren, Y. (2024) · Journal of Dermatological Treatment · doi:10.1080/09546634.2024.2333016 · Cited by 8
Biologicals for severe asthma: what we can learn from real-life experiences?
Bagnasco, D., Caminati, M., & Passalacqua, G. (2019) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000600 · Cited by 8
Iniciación a Tomás de Aquino: su persona y su obra
Torrell, J.-P. (2002) · Pensamiento Revista de investigación e información filosófica · Cited by 8
Physiopathologie de la dermatite atopique
Waton, J. (2017) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(18)30086-3 · Cited by 10
Paller, A. S., Marcoux, D., Ramien, M., Baselga, E., Carvalho, V. O., Ardusso, L., de Graaf, M., Pasmans, S. G. M. A., Toledo-Bahena, M. E., Rubin, C., et al. (2025) · American Journal of Clinical Dermatology · doi:10.1007/s40257-025-00962-8 · Cited by 9
Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose
Domingo, C., Rabe, K. F., Price, D. B., Brusselle, G., Wechsler, M. E., Xia, C., Pandit‐Abid, N., Gall, R., Rowe, P. J., Deniz, Y. M., et al. (2023) · ERJ Open Research · doi:10.1183/23120541.00056-2023 · Cited by 7
Ahn, T., Lee, D. H., Kim, G.-A., Kim, J., Park, J., Cho, H., & Kim, J. Y. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101148 · Cited by 7
Fine-tuning levels of filamins a and b as a specific mechanism sustaining Th2 lymphocyte functions
Maire, K., Chamy, L., Ghazali, S., Carratala-Lasserre, M., Zahm, M., Bouisset, C., Métais, A., Combes‐Soia, L., de la Fuente-Vizuete, L., Trad, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53768-3 · Cited by 8
Morandini, P., Laino, M. E., Paoletti, G., Carlucci, A., Tommasini, T., Angelotti, G., Pepys, J., Canonica, G. W., Heffler, E. M., Savevski, V., et al. (2022) · Clinical and Translational Allergy · doi:10.1002/clt2.12144 · Cited by 7
Xiong, H., Yang, J. P., Liu, T., Liu, G., Han, Y., & Dong, X. (2022) · Mediators of Inflammation · doi:10.1155/2022/6206883 · Cited by 7
Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma
Peters, A. T., Sagara, H., Corren, J., Domingo, C., Altincatal, A., Soler, X., Pandit‐Abid, N., Crikelair, N., Rowe, P. J., Jacob-Nara, J. A., et al. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.11.021 · Cited by 7
Mantia, I. L., Ottaviano, G., Ragusa, M., Trimarchi, M., Foglia, E., Schettini, F., Bellavia, D., & Cantone, E. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14040347 · Cited by 5
The role of deacetylase SIRT1 in allergic diseases
Lu, Y., Tang, X., Wang, W., Yang, H. J., & Wang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1422541 · Cited by 7
Cardiospermum halicacabum in atopic dermatitis: Clinical evidence based on phytotherapic approach
Fai, D., Fai, C., Vito, M. D., Martini, C., Zilio, G., & Togni, H. D. (2020) · Dermatologic Therapy · doi:10.1111/dth.14519 · Cited by 7
Immunomodulatory Properties of Polyphenol-Rich Sugarcane Extract on Human Monocytes
Feehan, J., Prakash, M. D., Stojanovska, L., Flavel, M., Kitchen, B., & Apostolopoulos, V. (2021) · Biologics · doi:10.3390/biologics1020013 · Cited by 7
Wan, H., Yang, H., Wei, M., & Chen, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-282 · Cited by 7
Thaçi, D., Bauer, A., von Kiedrowski, R., Schenck, F., Ertner, K., Möller, S., Fait, A., Bastian, M., & Augustin, M. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00791-1 · Cited by 7
Emerging systemic therapies for atopic dermatitis: biologics
Nusbaum, K. B., Nguyen, C., & Fleischer, A. B. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1836314 · Cited by 7
Exploring the efficacy and contribution of Dupilumab in asthma management
Alsaffar, R. M., & Alkholifi, F. K. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.03.119 · Cited by 7
Korn, S., Schmidt, O., Timmermann, H., Watz, H., Gappa, M., Radwan, A., Gómez, L. D. P., Atenhan, A., Barbus, S., Thakur, M., et al. (2023) · Respiration · doi:10.1159/000535390 · Cited by 8
Connecting the Dots: How MicroRNAs Link Asthma and Atherosclerosis
Zimbru, R.-I., Zimbru, E.-L., Bojin, F. M., Haidar, L., Andor, M., Harich, O. O., Tănasie, G., Tatu, C. S., Mailat, D.-E., Zbîrcea, I.-M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083570 · Cited by 6
Targeted Therapy for Severe Asthma: Identifying the Right Patients
Low, K., & Bardin, P. G. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0252-x · Cited by 6
The Role of Interleukin (IL)-6/IL-6 Receptor Axis in Cancer
Mir, M. A., Bashir, M., & Jan, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-4657-0_5 · Cited by 9
Tian, W., Blomberg, A. L., Steinberg, K., Henriksen, B. L., Jørgensen, J. S., Skovgaard, K., Skovbakke, S. L., & Goletz, S. (2024) · Glycobiology · doi:10.1093/glycob/cwae042 · Cited by 8
Efficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction
Israel, E., Castro, M., Ambrose, C. S., Llanos, J., Molfino, N. A., Martin, N. L., Ponnarambil, S. S., & Martin, N. (2024) · ERJ Open Research · doi:10.1183/23120541.00164-2024 · Cited by 7
Phipatanakul, W., Vogelberg, C., Bacharier, L. B., Dell, S., Altincatal, A., Gall, R., Ledanois, O., Sacks, H. J., Jacob-Nara, J. A., Deniz, Y. M., et al. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.27167 · Cited by 8
Gao, J., Li, D., Feng, Z., Zhu, X., Yang, F., Zhang, B., Hu, M., Wang, Y., Feng, H., Yu, Y., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117321 · Cited by 6
Li, Y., Yin, Y., Xiong, J., Zhang, Z., Li, L., Zhang, B., Zhang, F., & Mao, D. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s461769 · Cited by 6
Current and Emerging Biologics for Atopic Dermatitis
Nevid, M. Z., & Boguniewicz, M. (2024) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2024.08.001 · Cited by 7
Shou, L., He, H., Wei, Y., Xu, X., Wang, W., & Zheng, J. (2024) · Autoimmunity · doi:10.1080/08916934.2024.2427085 · Cited by 6
Bhatia, N. D., Lynde, C. W., Fonacier, L. S., Shao, L., Bosman, K., & Korotzer, A. R. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01395-1 · Cited by 6
Zhang, Z., Shi, L., Pang, W., Wang, X., Li, J., Wang, H., & Shi, G. (2016) · Allergy & Rhinology · doi:10.2500/ar.2016.7.0186 · Cited by 6
Liu, J., Lin, S., Wu, S., Lin, Q., Fan, Z., Wang, C., Ye, D., & Guo, P. (2023) · Journal of Animal Science · doi:10.1093/jas/skad362 · Cited by 6
Post-transcriptional regulation of interleukin-10 in peripheral B cells of airway allergy patients.
Luo, X., Yang, S., Qiu, S., Xie, R., Yang, L., Ke, Y.-X., Zhao, H., Geng, X., Yang, G., Liu, Z., et al. (2016) · PubMed Central · Cited by 6
The Changing Landscape of Atopic Dermatitis - Focusing on JAK Inhibitors
Rodrigues, M. A., & Torres, T. R. (2020) · European Annals of Allergy and Clinical Immunology · doi:10.23822/eurannaci.1764-1489.120 · Cited by 6
Raza, G., Yunus, F.-U.-N., Mangukiya, H. B., Merugu, S. B., Mashausi, D. S., Wang, Z., Negi, H., Zhou, B., Roy, D., Wu, Z., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107155 · Cited by 6
Simultaneous treatment of Samter triad and prurigo nodularis with dupilumab
Bloomstein, J. D., & Hawkes, J. E. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.10.005 · Cited by 6
Hassan-Nixon, H. A., Singh, N., & Cass, A. E. G. (2022) · Biosensors and Bioelectronics X · doi:10.1016/j.biosx.2022.100118 · Cited by 6
Type 2 Inflammation and the Evolving Profile of Uncontrolled Persistent Asthma
Saul, H. (2018) · European Medical Journal · doi:10.33590/emj/10314405 · Cited by 12
Immunological role of primary cilia of dendritic cells in human skin diseasePreprint
Toriyama, M., Rizaldy, D., Nakamura, M., Fujita, F., Okada, F., Morita, A., & Ishii, K. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.04.933333 · Cited by 7
Yan, X., & Li, L. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1422323 · Cited by 5
Vogelmeier, C. F., Rabe, K. F., Bhatt, S. P., Hanania, N. A., Bafadhel, M., Christenson, S. A., Papi, A. A., Singh, D., Laws, E., Maloney, J. M., et al. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108015 · Cited by 6
Targeting the IL-4/IL-4R Axis in Th2 Inflammatory Diseases: A Review of Clinical Efficacy and Safety
Li, W. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s558065 · Cited by 7
Mechanisms driving immunopathogenesis of viral exacerbations in chronic respiratory disease
McKenzie, J., Carter, C., Jackson, M. M., Singanayagam, A., & Shah, A. (2026) · Thorax · doi:10.1136/thorax-2024-222169 · Cited by 7
Biologics for eosinophilic COPD: current applications and future prospects
Qi, Q., Peng, W., Yang, B., Liu, S., Pu, Y., & Zhou, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1722371 · Cited by 5
Freeman, C. M., Curtis, J. L., & Hastie, A. T. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202305-0811ed · Cited by 5
CKBA suppresses mast cell activation via ERK signaling pathway in murine atopic dermatitis
Tong, J., Li, Y., Cai, X., Lou, F., Sun, Y., Wang, Z., Zheng, X., Zhou, H., Zhang, Z., Fang, Z., et al. (2023) · European Journal of Immunology · doi:10.1002/eji.202350374 · Cited by 5
Atopic Keratoconjunctivitis: Pathophysiology, Clinic, and Potential New Therapeutic Concepts
Lapp, T., Mann, C., Jakob, T., Reinhard, T., & Maier, P. C. (2024) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-2244-2885 · Cited by 6
Urinary eicosanoid levels in early life and risk of atopic disease in childhood
Chen, L., Brustad, N., Kim, M. G., Luo, Y., Wang, T., Ali, M., Prince, N., Chen, Y., Chu, S. H., Begum, S., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.05.022 · Cited by 6
Jia, L., Ma, M., Xiong, W., Zhu, J., Cai, Y., Chen, Y., Jin, J., & Gao, M. (2025) · Inflammation · doi:10.1007/s10753-024-02180-6 · Cited by 5
Biological treatment of severe asthma: new objectives and new treatment options
Nenasheva, N. M. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-15-50-61 · Cited by 5
Efficacy and safety of dupilumab in complex treatment of patients with severe atopic dermatitis
Kruglova, L. S., Шатохина, Е. А., & Руднева, Н. С. (2021) · Medical alphabet · doi:10.33667/2078-5631-2021-9-39-43 · Cited by 5
Dessì, A., Maria, C. D., Pintus, R., Fanos, V., & Bosco, A. (2023) · Current Pediatric Reviews · doi:10.2174/1573396320666230411093122 · Cited by 6
Costanzo, A., Furneri, G., Bitonti, R., Pedone, M. P., Fanelli, F., & Turi, R. D. (2020) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2020.710 · Cited by 5
The TGF‐β‐Th2 axis: A new target for cancer therapy?
de Durango, C. R. G., Escribese, M. M., & Rosace, D. (2021) · Allergy · doi:10.1111/all.14965 · Cited by 5
Examining Unmet Needs in the Management of Eosinophilic Esophagitis
Johnston, D. T. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88756 · Cited by 5
Toraldo, D. M., Rizzo, E., & Conte, L. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02237-z · Cited by 5
Zhang, J., Chen, J., Richardson, J. P., Francis, N.-J., Lai, P. F., Jenkins, K., Major, M. R., Key, R. E., Stewart, M. E., Firth‐Clark, S., et al. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00022 · Cited by 5
Comparison of cytokine mediators in type 2 inflammatory conditions on the skin and ocular surface
Chen, J., & Bielory, L. (2022) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000842 · Cited by 5
Kucharska, M., Kwiliński, K., Wawrzyńska, B., Cąkała, M., Kruszewski, A., Paduszyńska, N., Dąbrowska, A., Przybysz, P., & Szyszka, M. (2024) · Quality in Sport · doi:10.12775/qs.2024.19.54073 · Cited by 4
Aya, H., Araki‐Sasaki, K., Kobayashi, Y., Fukuda, K., & Imai, H. (2025) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2025.2529342 · Cited by 4
Bacharier, L. B., Maspero, J. F., Papadopoulos, N. G., Gagnon, R., Guilbert, T. W., Xia, C., Ledanois, O., & Soliman, M. (2025) · Pediatric Pulmonology · doi:10.1002/ppul.71197 · Cited by 4
Bhatt, S. P., Freemantle, N., Soliman, M., Heble, J., Cabon, Y., Herrera, E. M., Yang, J., & Xu, Y. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00322-1 · Cited by 5
Immunological control of skin development: from homeostasis to developmental pathologies
Wei, Y., Gu, J., Zhao, Z., & Gu, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1685633 · Cited by 5
Chen, Y., Yang, T., Zhang, J., Chen, X., Chen, X., Cheng, Z., Li, Y., Fan, X., Han, W., He, Z., et al. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.11.004 · Cited by 4
Mormile, I., Prova, D. L., Pezzella, P., Caprio, G. D., de Paulis, A., Cantone, E., & Detoraki, A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041525 · Cited by 4
Dupilumab normalizes the eosinophilic esophagitis disease transcriptome
Lim, W. K., Wipperman, M. F., Rothenberg, M. E., Collins, M. H., Hamon, S. C., Chehade, M., Spergel, J. M., Gayvert, K. M., Ehmann, P. J., Horowitz, J. E., et al. (2026) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2026.01.033 · Cited by 4
Self-citationGuilbert, T. W., Tolcachier, A., Fiocchi, A. G., Katelaris, C. H., Phipatanakul, W., Bégin, P., Messa, I. D. M., Altincatal, A., Gall, R., Ledanois, O., et al. (2024) · Journal of Asthma and Allergy · doi:10.2147/jaa.s416292 · Cited by 4
Noh, H. E., Rha, M., Jeong, Y., Kim, D., Seo, J. H., Kang, M., Moon, U. Y., Kim, C., & Cho, H. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29913 · Cited by 4
Circulating inflammatory cytokines and risk of aortic stenosis: A Mendelian randomization analysis
Qiu, X., Wu, J., Chen, Z., Zhang, Y., Cao, L., Wang, N., Teng, J., Su, C., Cheng, C., Fen, W., et al. (2025) · Cytokine · doi:10.1016/j.cyto.2025.156887 · Cited by 4
Sun, L., Ye, Y., Huang, S., Qin, X. G., Zeng, L., Guo, Y., Cheng, L., & Zhong, N. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003508 · Cited by 4
Wu, Y., Wang, Q., Zhu, W., Wang, D., Yong, Y., Li, W., & Sun, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-95280-8 · Cited by 6
Torretta, S., Piatti, G., Catalano, C., Ferrucci, S., Cavallini, M., Rivolta, F., Bellocchi, C., D’Adda, A., Battilocchi, L., Tavecchio, S., et al. (2025) · Therapeutic Advances in Allergy and Rhinology · doi:10.1177/27534030241312540 · Cited by 9
Letchumanan, G., & Say, Y. (2025) · International Journal of Immunogenetics · doi:10.1111/iji.70018 · Cited by 4
564 - Conjunctivitis adverse events in dupilumab clinical trials
Zirwas, M., Chovatiya, R., Gold, L. S., Shumel, B. S., Praestgaard, A. H., Chen, Z., Gonzalez, T., Gherardi, G., & Lawless, E. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljad498.060 · Cited by 4
Han, J.-Y., Kim, S.-K., Lim, D.-W., Kwon, O., Choi, Y.-R., Kang, C.-H., Lee, Y. J., & Lee, Y. (2024) · Nutrients · doi:10.3390/nu16223805 · Cited by 4
Calzavara‐Pinton, P., Chu, C., Lapeere, H., Rossi, M., Ferrucci, S. M., Chung, W., Fougerousse, A., Fomina, D. S., Holzer, G., Čelakovská, J., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03049-8 · Cited by 4
Metadata
- Authors
- Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D.
- Affiliations
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- Corresponding author
- Gandhi, Namita A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-10-16
- Volume
- 15
- Issue
- 1
- Pages
- 35-50
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2200308911
- Cited by
- 766
- References
- 156
- Citations by year
- 2026: 70 · 2025: 104 · 2024: 113 · 2023: 77 · 2022: 106 · 2021: 99 · 2020: 63 · 2019: 43 · 2018: 33 · 2017: 38 · 2016: 18
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Keywords
- type 2 inflammation, IL-4, IL-5, IL-13, asthma, atopic dermatitis, Th2 cells, allergic diseases, IL-4 receptor alpha inhibition, IL-13 inhibition, IL-5 inhibition, personalized asthma therapy, drug candidates
- MeSH terms
- Antibodies, Monoclonal, T-Lymphocytes, Helper-Inducer, Humans, Inflammation, Interleukin-4, Interleukin-5, Models, Immunological, Interleukin-13, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.